Olema Pharmaceuticals (OLMA) announced the FDA has cleared Investigational New Drug application for OP-3136, a small molecule that potently and selectively inhibits KAT6, a validated epigenetic target that is dysregulated in breast and other cancers. The company expects to initiate the Phase 1 clinical trial early next year.
"We are very pleased to have received notification from the FDA that OP-3136 may proceed into the clinic, said David Myles, Chief Discovery and Non-Clinical Development Officer of Olema Oncology.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.